Welcome to our dedicated page for QuidelOrtho SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QuidelOrtho's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QuidelOrtho's regulatory disclosures and financial reporting.
QuidelOrtho Corp (QDEL) reported that EVP Global Portfolio Management & Marketing Bryan Michael Hanson had 446 restricted stock units vest on August 15, 2026, converting into 446 shares of common stock. To satisfy related tax withholding obligations, 162 common shares were withheld by the company at $14.30 per share. Following this vesting event, the reported balance of these specific restricted stock units is 0.
Newtyn Management, LLC and Newtyn TE Partners, LP report their beneficial ownership of QuidelOrtho Corporation common stock in this amended Schedule 13G. As of June 30, 2026, Newtyn Management may be deemed to beneficially own 6,625,000 shares, representing 9.7% of QuidelOrtho’s common stock outstanding.
Within this amount, Newtyn TE Partners directly holds 4,266,500 shares, or 6.3% of the class, and Newtyn Partners, LP holds the remaining 2,358,500 shares. The reporting persons state sole voting and dispositive power over their reported holdings, based on 68,190,989 shares outstanding as of April 28, 2026.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 1,743,563 shares of QuidelOrtho Corp common stock, representing 2.6% of the class. The firm holds sole voting and dispositive power over all reported shares and states that its ownership is 5 percent or less of the class.
Invesco Ltd. filed as a significant shareholder of QuidelOrtho Corp, reporting beneficial ownership of 3,473,432 shares of common stock, representing 5.1% of the class. Invesco, a Bermuda company, reports this stake in its capacity as a parent holding company to its investment advisers.
Invesco has sole voting power over 3,455,098 shares and sole dispositive power over 3,473,432 shares, with no shared voting or dispositive power. The shares are held of record by clients of Invesco Ltd., and no single client has more than 5% economic ownership. Subsidiaries identified in connection with this holding are Invesco Advisers, Inc. and Invesco Capital Management LLC.
QuidelOrtho reported second quarter 2026 results with total revenue of $630.9 million, a 2.8% year-over-year increase, and a GAAP net loss of $92.9 million, or a loss of $1.36 per diluted share. Adjusted EBITDA was $129.3 million, a 20.5% margin, as Labs revenue grew 4% and Point of Care revenue grew 16%.
Revenue excluding China rose 6.1%, while China revenue declined 18.7%, reflecting pressure from proposed In Vitro Diagnostics pricing changes. QuidelOrtho cut its 2026 outlook to $2.52–$2.60 billion in revenue, $540–$560 million in adjusted EBITDA and $0.65–$0.90 adjusted EPS, and withdrew free cash flow guidance after using $143.6 million of operating cash in the first half.
Neuberger Berman Group LLC and Neuberger Berman Investment Advisers LLC report beneficial ownership of QuidelOrtho Corp common stock on a Schedule 13G/A. Neuberger Berman Group LLC is reported as beneficially owning 3,381,189 shares, representing 4.9% of the outstanding common shares.
The filing indicates no sole voting or dispositive power, with shared voting power over 2,720,194 shares and shared dispositive power over 3,381,189 shares. The report explains that various Neuberger Berman fiduciary entities may be deemed to beneficially own these securities under Exchange Act Rule 13d-3, but each entity disclaims beneficial ownership under Rule 13d-4. Securities managed by NB Alternatives Advisers LLC and other subsidiaries separated by an information barrier are expressly excluded.
Young Micah W reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp granted Chief Financial Officer Micah W. Young 356,555 restricted stock units, each representing one share of common stock. The award vests in three tranches: 118,851 units on July 15, 2027, and 118,852 units on each of July 15, 2028 and July 15, 2029, all held directly.
QuidelOrtho Corp executive Micah W. Young, Chief Financial Officer, filed an initial statement of beneficial ownership reporting that he holds no company securities. The Form 3 shows 0.0000 shares of QuidelOrtho Corp securities beneficially owned, with only a holding entry dated July 6, 2026.
QuidelOrtho Corp reports Neuberger Berman group holdings of 3,534,619 shares of Common Stock, representing 5.2% of the class. The filing lists CUSIP 219798105 and shows shared voting power of 2,722,100 shares and shared dispositive power of 3,534,619. The disclosure aggregates holdings across Neuberger Berman entities and notes fiduciary capacities and information barriers among subsidiaries.